INMB earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -1.09. Updated 2026-07-23.
INmune Bio (INMB) Research Hub
INmune Bio (INMB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.22 USD (-9.76%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.09, market cap 0.05B. This hub links to the full technical, earnings and options research available for INMB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.22 USD (-9.76%) |
| 52-week range | 1.25 USD – 2.6 USD |
| Trend regime | Range |
| 14-day RSI | 55.8 (Bullish) |
| Trailing P/E | -1.09 |
| Market cap | 0.05B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for INMB
Covered Call on INMB: how it works, illustrative setup around the real 2.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on INMB: how it works, illustrative setup around the real 2.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on INMB: how it works, illustrative setup around the real 2.22 USD price, max profit/loss, breakeven and when to use it. Educational.
INMB technical analysis: range, last 2.22 USD, RSI 55.8, 52w range 1.25 USD–2.6 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is INMB in?
INmune Bio (INMB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is INMB in an uptrend or downtrend?
As of 2026-09-11, INMB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is INMB's trailing P/E ratio?
INMB's trailing P/E is -1.09, with a market cap of 0.05B. See the earnings research page for full valuation detail.
When does INMB next report earnings?
INMB is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.20667 USD.